KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) EBIT Margin (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of EBIT Margin data on record, last reported at 28.51% in Q4 2025.

  • For Q4 2025, EBIT Margin fell 1178.0% year-over-year to 28.51%; the TTM value through Dec 2025 reached 0.63%, down 499.0%, while the annual FY2025 figure was 0.63%, 499.0% down from the prior year.
  • EBIT Margin reached 28.51% in Q4 2025 per CRL's latest filing, down from 13.32% in the prior quarter.
  • Across five years, EBIT Margin topped out at 19.26% in Q2 2022 and bottomed at 28.51% in Q4 2025.
  • Average EBIT Margin over 5 years is 10.81%, with a median of 14.84% recorded in 2022.
  • Peak YoY movement for EBIT Margin: skyrocketed 422bps in 2022, then crashed -2984bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 19.09% in 2021, then dropped by -22bps to 14.89% in 2022, then fell by -12bps to 13.12% in 2023, then tumbled by -228bps to 16.73% in 2024, then plummeted by -70bps to 28.51% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 28.51% in Q4 2025, 13.32% in Q3 2025, and 9.7% in Q2 2025.